Ralph Alvarez
Ralph Alvarez's purchase track record
Ralph Alvarez has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2025 | LLY | $500K | +54.4% | +54.3% | +7.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
First Watch (FWRG) Featured in Growth Stock Roundups. First Watch Restaurant Group was highlighted in recent market roundups as a growth stock to watch, alongside other consumer discretionary names moving in after-hours trading. The company is currently trading near the upper end of its 52-week range, with an average analyst target of $19.10. These mentions reflect ongoing interest in the brand's expansion potential within the restaurant sector.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
COOK: Traeger awaits Lowe's 2027 rollout. Traeger indicated that it expects its partnership with Lowe’s to begin rolling out products in 2027. The timing suggests that any impact on sales will be several years away. The stock is currently trading near a support level that has been tested many times, which may be observed as the company plans for the future rollout.
Transaction History
| LLY | ▲ Buy | Grant | 11 | $12K | 9/21/2026 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $12K | 8/17/2026 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $12K | 7/20/2026 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $12K | 6/15/2026 | View on chart |
| FWRG | ▲ Buy | Grant | 17,636 | $0 | 5/21/2026 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 5/18/2026 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 4/20/2026 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 3/16/2026 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $12K | 2/17/2026 | View on chart |
| COOK | ▲ Buy | Grant | 37,500 | $0 | 2/2/2026 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $12K | 1/20/2026 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $12K | 12/15/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $12K | 11/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 215 | $220K | 11/17/2025 | View on chart |
| COOK | ▲ Buy | Grant | 44,836 | $0 | 11/3/2025 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $12K | 10/20/2025 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $12K | 9/15/2025 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $12K | 8/18/2025 | View on chart |
| LLY | ▲ Buy | Open Market | 758 | $500K | 8/13/2025 | View on chart |
| COOK | ▲ Buy | Grant | 25,152 | $0 | 8/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $12K | 7/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $12K | 6/16/2025 | View on chart |
| FWRG | ▲ Buy | Grant | 12,570 | $0 | 5/22/2025 | View on chart |
| COOK | ▲ Buy | Grant | 131,849 | $0 | 5/20/2025 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $12K | 5/19/2025 | View on chart |
| COOK | ▲ Buy | Grant | 28,253 | $0 | 5/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 14 | $12K | 4/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 14 | $12K | 3/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 14 | $12K | 2/18/2025 | View on chart |
| COOK | ▲ Buy | Grant | 16,905 | $0 | 1/31/2025 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $12K | 1/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $12K | 12/16/2024 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $12K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 303 | $220K | 11/18/2024 | View on chart |
| COOK | ▲ Buy | Grant | 13,095 | $0 | 10/31/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 10/21/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 9/16/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 8/19/2024 | View on chart |
| COOK | ▲ Buy | Grant | 16,905 | $0 | 8/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $11K | 7/15/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $12K | 6/17/2024 | View on chart |
| COOK | ▲ Buy | Grant | 76,086 | $0 | 6/11/2024 | View on chart |
| FWRG | ▲ Buy | Grant | 7,792 | $0 | 5/23/2024 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $12K | 5/20/2024 | View on chart |
| COOK | ▲ Buy | Grant | 19,186 | $0 | 5/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $12K | 4/15/2024 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $11K | 3/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $12K | 2/20/2024 | View on chart |
| COOK | ▲ Buy | Grant | 18,835 | $0 | 2/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 19 | $12K | 1/16/2024 | View on chart |
| LLY | ▲ Buy | Grant | 20 | $12K | 12/18/2023 | View on chart |
| LLY | ▲ Buy | Grant | 19 | $11K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 335 | $200K | 11/20/2023 | View on chart |
| COOK | ▲ Buy | Grant | 15,277 | $0 | 10/31/2023 | View on chart |
| LLY | ▲ Buy | Grant | 18 | $11K | 10/16/2023 | View on chart |
| LLY | ▲ Buy | Grant | 20 | $11K | 9/18/2023 | View on chart |
| LLY | ▲ Buy | Grant | 21 | $12K | 8/21/2023 | View on chart |
| COOK | ▲ Buy | Grant | 9,417 | $0 | 7/31/2023 | View on chart |
| LLY | ▲ Buy | Grant | 25 | $11K | 7/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 25 | $11K | 6/20/2023 | View on chart |
| COOK | ▲ Buy | Grant | 52,739 | $0 | 5/30/2023 | View on chart |
| FWRG | ▲ Buy | Grant | 8,333 | $0 | 5/24/2023 | View on chart |
| LLY | ▲ Buy | Grant | 26 | $11K | 5/15/2023 | View on chart |
| COOK | ▲ Buy | Grant | 13,613 | $0 | 4/28/2023 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $11K | 4/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 34 | $11K | 3/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 35 | $11K | 2/21/2023 | View on chart |
| COOK | ▲ Buy | Grant | 11,991 | $0 | 2/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $11K | 1/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $11K | 12/19/2022 | View on chart |
| LLY | ▲ Buy | Grant | 31 | $11K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 498 | $180K | 11/21/2022 | View on chart |
| COOK | ▲ Buy | Grant | 9,963 | $0 | 10/31/2022 | View on chart |
| LLY | ▲ Buy | Grant | 34 | $11K | 10/17/2022 | View on chart |
| LLY | ▲ Buy | Grant | 37 | $11K | 9/19/2022 | View on chart |
| LLY | ▲ Buy | Grant | 36 | $11K | 8/15/2022 | View on chart |
| COOK | ▲ Buy | Grant | 13,436 | $0 | 7/29/2022 | View on chart |
| LLY | ▲ Buy | Grant | 35 | $11K | 7/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 38 | $11K | 6/21/2022 | View on chart |
| COOK | ▲ Buy | Grant | 45,942 | $0 | 6/14/2022 | View on chart |
| FWRG | ▲ Buy | Grant | 10,281 | $0 | 5/25/2022 | View on chart |
| LLY | ▲ Buy | Grant | 38 | $11K | 5/16/2022 | View on chart |
| COOK | ▲ Buy | Grant | 6,886 | $0 | 4/29/2022 | View on chart |
| LLY | ▲ Buy | Grant | 38 | $11K | 4/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 39 | $11K | 3/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 47 | $11K | 2/22/2022 | View on chart |
| COOK | ▲ Buy | Grant | 4,392 | $0 | 1/28/2022 | View on chart |
| LLY | ▲ Buy | Grant | 46 | $11K | 1/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 41 | $0 | 12/20/2021 | View on chart |
| LLY | ▲ Buy | Grant | 677 | $175K | 11/15/2021 | View on chart |
| LLY | ▲ Buy | Grant | 42 | $11K | 11/15/2021 | View on chart |
| COOK | ▲ Buy | Grant | 1,424 | $0 | 10/29/2021 | View on chart |
| LLY | ▲ Buy | Grant | 46 | $11K | 10/18/2021 | View on chart |
| LLY | ▲ Buy | Grant | 47 | $11K | 9/20/2021 | View on chart |
| LLY | ▲ Buy | Grant | 40 | $11K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.